Latest ArticlesEN-USSat, 17 Mar 2018 14:13:58 -0400936018
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PTzAzq0iyWs/intercept-icpt-up-67-since-earnings-report-can-it-continue-cm936018
Intercept (ICPT) Up 6.7% Since Earnings Report: Can It Continue?It has been about a month since the last earnings report for Intercept Pharmaceuticals Inc ICPT Shares have added about 6 7 in that time frame Will the recent positive trend continue leading up to its next earnings release or is ICPT due for a pullback Before we dive into how<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/PTzAzq0iyWs" height="1" width="1" alt=""/>Fri, 16 Mar 2018 18:08:14 Z2018-03-16T18:08:14Zhttp://www.nasdaq.com/article/intercept-icpt-up-67-since-earnings-report-can-it-continue-cm936018931864
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0IYLus8xHk8/2-cheap-growth-stocks-to-buy-right-now-cm931864
2 Cheap Growth Stocks to Buy Right NowGrowth stocks are an essential component of any well rounded portfolio However it s become increasingly difficult to find growth stocks trading at reasonable valuations in this aging bull market Even so I think there are still some attractive bargains available Within<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/0IYLus8xHk8" height="1" width="1" alt=""/>Thu, 08 Mar 2018 15:51:09 Z2018-03-08T15:51:09Zhttp://www.nasdaq.com/article/2-cheap-growth-stocks-to-buy-right-now-cm931864931837
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rLYb3EiIb_k/analysts-forecast-12-upside-for-eqal-cm931837
Analysts Forecast 12% Upside For EQALLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/rLYb3EiIb_k" height="1" width="1" alt=""/>Thu, 08 Mar 2018 15:48:55 Z2018-03-08T15:48:55Zhttp://www.nasdaq.com/article/analysts-forecast-12-upside-for-eqal-cm931837921992
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_eNXm6Sq4oE/intercept-icpt-q4-earnings-sales-lag-on-dull-ocaliva-cm921992
Intercept (ICPT) Q4 Earnings & Sales Lag on Dull OcalivaIntercept Pharmaceuticals Inc ICPT reported disappointing results for fourth quarter 2017 on account of drab Ocaliva sales The company reported a loss of 4 43 per share in the fourth quarter wider than the Zacks Consensus Estimate of 3 57 but narrower than the year ago loss of 4<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/_eNXm6Sq4oE" height="1" width="1" alt=""/>Thu, 15 Feb 2018 15:26:34 Z2018-02-15T15:26:34Zhttp://www.nasdaq.com/article/intercept-icpt-q4-earnings-sales-lag-on-dull-ocaliva-cm921992921416
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l2HS9v5UsK8/intercept-icpt-misses-on-q4-earnings-sales-cm921416
Intercept (ICPT) Misses on Q4 Earnings & SalesNew York based Intercept Pharmaceuticals Inc ICPT focused on bringing novel therapeutics to treat chronic liver diseases to market Intercept received a major boost with the FDA approval in May 2016 of its lead drug Ocaliva in combination with ursodeoxycholic UDCA for the treatment<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/l2HS9v5UsK8" height="1" width="1" alt=""/>Wed, 14 Feb 2018 16:13:19 Z2018-02-14T16:13:19Zhttp://www.nasdaq.com/article/intercept-icpt-misses-on-q4-earnings-sales-cm921416920599
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eaC8QpnWc4g/intercept-starts-oca-trial-for-nash-patients-with-cirrhosis-cm920599
Intercept Starts OCA Trial for NASH Patients With CirrhosisIntercept Pharmaceuticals Inc ICPT initiated a phase III trial REVERSE on obeticholic acid OCA The randomized phase III study will evaluate the efficacy and safety of OCA in subjects with compensated cirrhosis due to non alcoholic steatohepatitis NASH in approximately 540<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/eaC8QpnWc4g" height="1" width="1" alt=""/>Tue, 13 Feb 2018 15:11:44 Z2018-02-13T15:11:44Zhttp://www.nasdaq.com/article/intercept-starts-oca-trial-for-nash-patients-with-cirrhosis-cm920599919993
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lOAclpHnCVI/will-ocaliva-sales-dampen-intercepts-icpt-q4-earnings-cm919993
Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?Intercept Pharmaceuticals Inc ICPT is scheduled to report fourth quarter 2017 results on Feb 14 before the opening bell Last quarter the company reported a narrower than expected loss Let s see how things are shaping up for this announcement Intercept s stock has<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/lOAclpHnCVI" height="1" width="1" alt=""/>Mon, 12 Feb 2018 14:08:50 Z2018-02-12T14:08:50Zhttp://www.nasdaq.com/article/will-ocaliva-sales-dampen-intercepts-icpt-q4-earnings-cm91999320180201-01851
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zdBqjisyiwU/agns-superbug-antibiotic-gets-fda-nod-afmd-soars-boxed-warning-for-ocaliva-20180201-01851
AGN's Superbug Antibiotic Gets FDA Nod, AFMD Soars, Boxed Warning For OcalivaAGN's Superbug Antibiotic Gets FDA Nod, AFMD Soars, Boxed Warning For Ocaliva<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/zdBqjisyiwU" height="1" width="1" alt=""/>Thu, 01 Feb 2018 22:11:00 Z2018-02-01T22:11:00Zhttp://www.nasdaq.com/article/agns-superbug-antibiotic-gets-fda-nod-afmd-soars-boxed-warning-for-ocaliva-20180201-01851914831
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SCgirlYxSas/biotech-roundup-whos-popping-on-drug-merger-earnings-news-cm914831
Biotech Roundup: Who's Popping On Drug, Merger, Earnings News?Intercept Pharmaceuticals ICPT Seattle Genetics SGEN and Corcept Therapeutics CORT rose above the froth Thursday popping on key drug merger and earnings news even as the biotech group remained flat ibd display video id 3119852 width 50 float<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/SCgirlYxSas" height="1" width="1" alt=""/>Thu, 01 Feb 2018 22:02:39 Z2018-02-01T22:02:39Zhttp://www.nasdaq.com/article/biotech-roundup-whos-popping-on-drug-merger-earnings-news-cm914831914904
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pfflmm-YnzI/noteworthy-thursday-option-activity-xom-now-icpt-cm914904
Noteworthy Thursday Option Activity: XOM, NOW, ICPTLooking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Exxon Mobil Corp Symbol XOM where a total volume of 48 014 contracts has been traded thus far today a contract volume which is representative of approximately 4 8<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Pfflmm-YnzI" height="1" width="1" alt=""/>Thu, 01 Feb 2018 21:57:51 Z2018-02-01T21:57:51Zhttp://www.nasdaq.com/article/noteworthy-thursday-option-activity-xom-now-icpt-cm91490420180116-00016
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XtcfsD5iBv8/the-race-to-find-a-treatment-for-nash-20180116-00016
The Race To Find A Treatment For NASHThe Race To Find A Treatment For NASH<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/XtcfsD5iBv8" height="1" width="1" alt=""/>Tue, 16 Jan 2018 01:03:00 Z2018-01-16T01:03:00Zhttp://www.nasdaq.com/article/the-race-to-find-a-treatment-for-nash-20180116-00016904656
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O8Eo6rHPz84/the-primary-reason-intercept-pharmaceuticals-inc-was-nearly-halved-in-2017-cm904656
The Primary Reason Intercept Pharmaceuticals, Inc. Was Nearly Halved in 2017What happened Shares of Intercept Pharmaceuticals NASDAQ ICPT a biopharmaceutical company focused on the development of therapies to treat diseases of the liver collapsed and fell 46 in 2017 according to data from S amp P Global Market Intelligence The reason<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/O8Eo6rHPz84" height="1" width="1" alt=""/>Fri, 12 Jan 2018 17:09:04 Z2018-01-12T17:09:04Zhttp://www.nasdaq.com/article/the-primary-reason-intercept-pharmaceuticals-inc-was-nearly-halved-in-2017-cm904656898263
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yjqqMLYjPYs/intercept-icpt-stock-loses-sheen-in-2017-what-lies-ahead-cm898263
Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?Shares of Intercept Pharmaceuticals Inc ICPT have declined 42 3 in 2017 as against the industry s 5 2 rally Intercept s lead drug Ocaliva was approved in the United States in combination with ursodeoxycholic UDCA for the treatment of primary biliary cholangitis PBC<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/yjqqMLYjPYs" height="1" width="1" alt=""/>Fri, 29 Dec 2017 15:13:54 Z2017-12-29T15:13:54Zhttp://www.nasdaq.com/article/intercept-icpt-stock-loses-sheen-in-2017-what-lies-ahead-cm898263897939
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vnHzWlvkoUA/this-biotech-stock-just-pushed-back-a-key-trial-until-early-2018-cm897939
This Biotech Stock Just Pushed Back A Key Trial Until Early 2018Intercept Pharmaceuticals ICPT will push a Phase 3 study of its liver disease drug Ocaliva in cirrhotic nonalcoholic steatohepatitis into the first quarter an analyst said Thursday ibd display video id 3049836 width 50 float left autostart true The decision was<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/vnHzWlvkoUA" height="1" width="1" alt=""/>Thu, 28 Dec 2017 22:07:52 Z2017-12-28T22:07:52Zhttp://www.nasdaq.com/article/this-biotech-stock-just-pushed-back-a-key-trial-until-early-2018-cm897939877469
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qj0VkxqOo1o/7-life-science-stocks-to-buy-today-cm877469
7 Life Science Stocks to Buy TodayInvestorPlace Stock Market News Stock Advice amp Trading Tips Biotech and life sciences stocks have had a great run up so far in 2017 Through the end of October the S amp P Biotechnology Select Sector Industry Index SPSIBI is up 52 That makes the life science stocks some of<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Qj0VkxqOo1o" height="1" width="1" alt=""/>Wed, 15 Nov 2017 00:48:15 Z2017-11-15T00:48:15Zhttp://www.nasdaq.com/article/7-life-science-stocks-to-buy-today-cm877469875743
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tB5MRQzmGEY/notable-friday-option-activity-icpt-gild-clvs-cm875743
Notable Friday Option Activity: ICPT, GILD, CLVSAmong the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Intercept Pharmaceuticals Inc Symbol ICPT where a total of 5 390 contracts have traded so far representing approximately 539 000 underlying shares That amounts to about 55 of ICPT<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/tB5MRQzmGEY" height="1" width="1" alt=""/>Fri, 10 Nov 2017 22:09:11 Z2017-11-10T22:09:11Zhttp://www.nasdaq.com/article/notable-friday-option-activity-icpt-gild-clvs-cm875743870367
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cqJHExvHkL4/intercept-icpt-q3-loss-narrower-than-expected-sales-beat-cm870367
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales BeatIntercept Pharmaceuticals Inc ICPT reported encouraging results for third quarter 2017 The company posted a loss of 2 89 per share in the third quarter narrower than the Zacks Consensus Estimate of 3 55 and the year ago loss of 3 59 Intercept Pharmaceuticals Inc Price and<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/cqJHExvHkL4" height="1" width="1" alt=""/>Thu, 02 Nov 2017 16:02:52 Z2017-11-02T16:02:52Zhttp://www.nasdaq.com/article/intercept-icpt-q3-loss-narrower-than-expected-sales-beat-cm870367